-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Imiquimod
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/99011-02-6.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 99011-02-6 |
| Description | An agonist of TLR7 with immune response modifying activity, Approved for basal cell carcinoma, In Phase III for VIN and CIN, Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. |
Product Information
| Synonyms | 1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; R-837; S-26308; Aldara; TMX-101; 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine; Aldara; Beselna; Keravort; R 837; R837; S 26308; TMX 101; Zartra; Zyclara |
| IUPAC Name | 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine |
| Molecular Weight | 240.30 |
| Molecular Formula | C14H16N4 |
| Canonical SMILES | CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N |
| InChI | InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) |
| InChIKey | DOUYETYNHWVLEO-UHFFFAOYSA-N |
| Boiling Point | 456.7±48.0°C at 760 mmHg |
| Melting Point | 292-294°C |
| Flash Point | 230.0±29.6 °C |
| Purity | >98% |
| Density | 1.28±0.1 g/cm3 |
| Solubility | Soluble in Aqueous Acid (Slightly), DMSO (Very Slightly, Heated) |
| Appearance | Off-White Solid |
| Application | An immune response modifier. It stimulates the production of interferon-a |
| Shelf Life | ≥98% |
| Storage | Store at -20°C |
| Complexity | 294 |
| Exact Mass | 240.137496527 |
| Index Of Refraction | 1.681 |
| In Vivo | In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secretecytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α. |
| PSA | 56.73000 |
| Target | Toll-like Receptor (TLR); Autophagy; SARS-CoV; HSV |
| Vapor Pressure | 0.0±1.1 mmHg at 25°C |
| XLogP3-AA | 2.6 |
